Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (HEPA) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic liver diseases through its proprietary cyclophilin inhibitor platform. This page provides investors and industry stakeholders with timely updates on material developments including clinical trial progress, regulatory milestones, and strategic partnerships.
Our curated news feed delivers essential updates on HEPA's lead candidate CRV431, a pipeline targeting fibrosis, hepatocellular carcinoma, and viral hepatitis. Users will find verified information on Phase 2/3 trial results, FDA communications, and collaborative research initiatives without promotional bias.
The repository includes press releases covering three key areas: clinical development updates detailing patient enrollment and trial outcomes, business strategy announcements regarding licensing agreements, and scientific presentations at hepatology conferences. All content is vetted for material relevance to investment analysis and therapeutic advancement.
Bookmark this page for direct access to Hepion's latest developments in pleiotropic liver disease therapies. Check regularly for updates that may influence long-term valuation assessments in the competitive hepatology therapeutics sector.
On April 17, 2023, Hepion Pharmaceuticals (NASDAQ:HEPA) announced that an abstract regarding its lead drug candidate, rencofilstat, will be presented by Chief Scientific Officer Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting in Orlando, Florida, from April 15-19, 2023. The presentation, titled Rencofilstat Exerts a Dominant Role in Synergistic Anti-PD1-Combination Effects in a Fatty Liver Model of Hepatocellular Carcinoma, is scheduled for April 18, 2023, from 9:00 AM to 12:30 PM ET. Rencofilstat is currently in Phase 2 clinical trials for treating non-alcoholic steatohepatitis (NASH) and has received Fast Track and Orphan Drug designations from the FDA for its potential applications. The company utilizes its proprietary AI platform, AI-POWR™, for precision medicine in identifying responsive NASH patients.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
